- Active not recruitingPHASE3
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
This study, called POSEIDON, is testing new drug combinations for people with a type of lung cancer called non-small cell lung cancer (NSCLC). It's comparing usual chemotherapy with combinations of two new drugs, durvalumab and tremelimumab, to see if they work better.
For: Non Small Cell Lung Cancer NSCLCUnited States · Brazil · Bulgaria - Active not recruitingPHASE3
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
This study looks at new drug combinations for bladder cancer that has spread into the muscle. It compares them to standard treatment for people who can't take or don't want cisplatin chemotherapy before surgery to remove their bladder. The aim is to find more effective and safe options.
For: Muscle Invasive Bladder CancerUnited States · Argentina · Austria - RecruitingPHASE3
Renal Adjuvant MultiPle Arm Randomised Trial
This study looks at new treatments for kidney cancer (renal cell carcinoma) after surgery. It compares two drugs, durvalumab and tremelimumab, given alone or together, against standard monitoring. The aim is to see if these drugs can stop the cancer from coming back or help people live longer.
For: Renal Cell CarcinomaUnited Kingdom - Active not recruitingPHASE3
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
This study looks at new treatments (Durvalumab, Tremelimumab) for a type of lung cancer, Small Cell Lung Cancer, after initial strong treatment. It aims to see if these drugs can stop the cancer from coming back.
For: Small Cell Lung CancerUnited States · Argentina · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
ADJUBIL - A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in ADJUvant situation for BILiary tract cancer
This study is looking at new treatments for a type of cancer called biliary tract cancer after surgery. It combines existing cancer drugs with new immunotherapy drugs, durvalumab and tremelimumab. The aim is to see if these combinations can stop the cancer from coming back and improve how long people live well.
For: Biliary tract cancerGermany - AuthorisedTherapeutic exploratory (Phase II)
Perioperative Therapy with Durvalumab Plus Tremelimumab for Patients with Resectable Hepatocellular Carcinoma (HCC) - A Phase II Trial (NEOTOMA)
This study is testing two medicines, durvalumab and tremelimumab, before surgery for liver cancer. We want to see if these medicines cause side effects that stop surgery or are hard to manage. It's a Phase II trial, meaning we're looking at safety and early signs of how well it works.
For: Resectable Hepatocellular CarcinomaSpain · Italy - RecruitingPHASE3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
This study is testing new combinations of medicines for advanced liver cancer (hepatocellular carcinoma) that can't be cured with surgery. It compares different drug blends to a common treatment to see which works best and is safest.
For: Hepatocellular CarcinomaUnited States · Australia · Brazil - Active not recruitingPHASE3
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
This study looks at new drug combinations for advanced bladder cancer that hasn't been treated before. It compares them to standard chemotherapy to see if they're safer and work better.
For: Urothelial CancerUnited States · Australia · Austria - Active not recruitingPHASE2
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
This study is testing a new drug, tremelimumab, against a dummy treatment (placebo) for people with a type of cancer called malignant mesothelioma that cannot be removed by surgery. It aims to see if the new drug can help patients.
For: Unresectable Pleural or Peritoneal Malignant MesotheliomaUnited States · Australia · Belgium